BioCryst Pharmaceuticals (BCRX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.35
- Estimate
- $0.24
- Surprise
- +49.4%
- Revenue (period 2026-06-30)
- $218.3M
- Score at report (before → after)
- 6.5 → 6.3/10
Revenue source: xbrl.
How the report landed
BioCryst Pharmaceuticals (BCRX) beat the $0.24 estimate with adjusted EPS of $0.35 — a large 49.4% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.5/10) to Hold at 6.3/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BCRX Buy (Wait) at 6.6/10.
4 of the last 4 quarters beat the estimate; this quarter's +49.4% surprise compares with a +101.4% four-quarter average. Next scheduled report: 2027-02-25.
What supports the rating
- Strong earnings beat streak (4/4)
- High-quality business
What argues against it
- Negative momentum
- Elevated risk factors
- Momentum score 3.1/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.45
- Entry target
- $7.08
- Price target
- $17.80
- Stop
- $6.58
- Upside to target
- +138.9%
- Reward-to-risk
- 13.8:1
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
BCRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.96B
- P/E (fwd)
- 8.9
- 52-week range
- $6.23–$11.22
- Off 52-week high
- 33.6%
- RSI (14)
- 37
- Volume vs avg
- 0.76×
- Score today
- 6.6/10